NEW YORK (GenomeWeb News) — Illumina will handle genotyping services for a joint study for the Type I Diabetes Genetics Consortium that aims to identify genes that influence the risk of developing the disease.
Illumina said it will provide its Fast Track Genotyping Services to process more than 6,500 samples for the study, which is being conducted by the Center for Public Health Genomics at the University of Virginia for the National Institute of Diabetes and Digestive and Kidney Diseases.
Illumina will use its HumanHap550-Duo BeadChip platform for the study. Once the diabetes-linked genes have been identified, "researchers can then use this information to develop better approaches to detecting, treating, and preventing the disease," said Stephen Rich, director of the CPHG.
Financial terms of the agreement were not released.